Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

NCT01519427 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Stopped Study terminated due to slow accrual

Conditions

Recurrent Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions

DRUG: Akt inhibitor MK2206
DRUG: selumetinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)